GARADACIMAB

garadacimab 200 mg/1.2 mL injection, 1.2 mL pen device

GARADACIMAB (15317E)

garadacimab 200 mg/1.2 mL injection, 1.2 mL pen device
15317E
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Chronic treatment of hereditary angioedema Types 1 or 2
Treatment phase: Initial 1: New patient (commencing with no previous treatment with C1-INH for routine prophylaxis)

Restriction

Indication: Chronic treatment of hereditary angioedema Types 1 or 2
Treatment phase: Initial 2: New patient (commencing from National Blood Authority-funded C1-INH)

Restriction

Indication: Chronic treatment of hereditary angioedema Types 1 or 2
Treatment phase: Initial 3: New patient (transitioning from PBS-subsidised lanadelumab)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 2 Max qty units: 2 # of repeats: 0 DPMQ: $60,188.20 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Andembry